Q2 2018 Earnings Forecast for Hill-Rom Holdings, Inc. Issued By KeyCorp (HRC)

Hill-Rom Holdings, Inc. (NYSE:HRC) – Equities research analysts at KeyCorp decreased their Q2 2018 EPS estimates for Hill-Rom in a research note issued on Friday. KeyCorp analyst M. Mishan now anticipates that the medical technology company will post earnings of $1.02 per share for the quarter, down from their previous forecast of $1.04. KeyCorp has a “Buy” rating and a $97.00 price objective on the stock. KeyCorp also issued estimates for Hill-Rom’s Q3 2018 earnings at $1.17 EPS and Q4 2018 earnings at $1.50 EPS.

Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, January 26th. The medical technology company reported $0.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.13. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The firm had revenue of $669.70 million during the quarter, compared to analyst estimates of $670.00 million. During the same quarter in the prior year, the business earned $0.75 earnings per share. Hill-Rom’s revenue for the quarter was up 5.1% on a year-over-year basis.

HRC has been the subject of a number of other research reports. ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Raymond James Financial upgraded shares of Hill-Rom from a “market perform” rating to an “outperform” rating and set a $94.00 target price for the company in a research report on Wednesday, January 3rd. Barclays upped their target price on shares of Hill-Rom from $86.00 to $90.00 and gave the stock an “overweight” rating in a research report on Monday, November 6th. Finally, Needham & Company LLC restated a “buy” rating on shares of Hill-Rom in a research report on Friday. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Hill-Rom currently has an average rating of “Buy” and an average target price of $95.38.

Hill-Rom (NYSE HRC) opened at $88.22 on Monday. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.34 and a current ratio of 1.77. Hill-Rom has a 12-month low of $57.18 and a 12-month high of $91.11. The firm has a market cap of $5,810.00, a price-to-earnings ratio of 29.91, a P/E/G ratio of 1.61 and a beta of 1.19.

In related news, CEO John J. Greisch sold 125,241 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the sale, the chief executive officer now owns 280,851 shares of the company’s stock, valued at $23,195,484.09. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total transaction of $82,990.00. Following the sale, the senior vice president now directly owns 1,066 shares in the company, valued at approximately $88,467.34. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 226,241 shares of company stock worth $18,708,644. 2.20% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its stake in shares of Hill-Rom by 173.1% in the fourth quarter. SG Americas Securities LLC now owns 45,643 shares of the medical technology company’s stock valued at $3,847,000 after acquiring an additional 28,932 shares during the period. State of Alaska Department of Revenue purchased a new stake in shares of Hill-Rom in the fourth quarter valued at $429,000. Fox Run Management L.L.C. raised its stake in shares of Hill-Rom by 190.4% in the fourth quarter. Fox Run Management L.L.C. now owns 8,130 shares of the medical technology company’s stock valued at $685,000 after acquiring an additional 5,330 shares during the period. CAPROCK Group Inc. purchased a new stake in shares of Hill-Rom in the fourth quarter valued at $211,000. Finally, Creative Planning raised its stake in shares of Hill-Rom by 6.8% in the fourth quarter. Creative Planning now owns 20,174 shares of the medical technology company’s stock valued at $1,700,000 after acquiring an additional 1,287 shares during the period. 82.00% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Q2 2018 Earnings Forecast for Hill-Rom Holdings, Inc. Issued By KeyCorp (HRC)” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/29/q2-2018-earnings-forecast-for-hill-rom-holdings-inc-issued-by-keycorp-hrc.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply